^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE4 inhibitor

    Related drugs:
    1d
    Ulcerative pyoderma gangrenosum in a 78-year-old woman treated with brodalumab: A case report. (PubMed, SAGE Open Med Case Rep)
    The patient was refractory to corticosteroids, dapsone, and roflumilast, and developed recurrent Gram-negative infections. Brodalumab may offer a safe and effective treatment option in refractory pyoderma gangrenosum, particularly in patients with contraindications to conventional therapies. This case supports further evaluation of IL-17 pathway inhibition in neutrophilic dermatoses.
    Journal
    |
    IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A)
    4d
    Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (clinicaltrials.gov)
    P=N/A, N=106, Not yet recruiting, Cairo University
    New trial
    6d
    Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis (clinicaltrials.gov)
    P1, N=16, Recruiting, Arcutis Biotherapeutics, Inc.
    New P1 trial
    7d
    A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (clinicaltrials.gov)
    P3, N=3973, Terminated, Chiesi Farmaceutici S.p.A. | Active, not recruiting --> Terminated; Strategic decision by Sponsor; not due to safety reasons
    Trial termination
    7d
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=176, Completed, VA Office of Research and Development | Recruiting --> Completed | N=120 --> 176 | Trial completion date: Jun 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Eyevinal (ibudilast)
    11d
    A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P2 trial
    11d
    Human Laboratory Study of Apremilast for Alcohol Use Disorder (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    New P2 trial
    12d
    A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=33, Completed, Verona Pharma plc | Active, not recruiting --> Completed
    Trial completion
    14d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    ESSENCE: A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (clinicaltrials.gov)
    P3, N=203, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion
    18d
    A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Ganzhou Hemay Pharmaceutical Co., Ltd
    New P2 trial
    27d
    Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects (clinicaltrials.gov)
    P1, N=90, Recruiting, Beijing Tide Pharmaceutical Co., Ltd
    New P1 trial